Table 2.
Baseline characteristics
| Placebo (n=16) | AZD8931 (n=16) | ||
|---|---|---|---|
| Age (years) | 64 (58–74) | 65 (57–71) | |
| Sex | |||
| Male | 13 (81%) | 13 (81%) | |
| Female | 3 (19%) | 3 (19%) | |
| Current state of primary tumour | |||
| Resected primary | 11 (69%) | 8 (50%) | |
| Unresected primary | 5 (31%) | 7 (44%) | |
| Unresected local recurrence | 0 | 1 (6%) | |
| Timing of metastases | |||
| Metachronous | 4 (25%) | 4 (25%) | |
| Synchronous | 12 (75%) | 11 (69%) | |
| Missing data | 0 | 1 (6%) | |
| Site of primary of tumour | |||
| Right colon | 5 (31%) | 5 (31%) | |
| Left colon | 6 (38%) | 6 (38%) | |
| Rectum | 5 (31%) | 5 (31%) | |
| WHO performance status | |||
| 0 | 12 (75%) | 11 (69%) | |
| 1 or 2 | 4 (25%) | 5 (31%) | |
| Disease assessment at end of first-line treatment | |||
| Partial response | 8 (50%) | 7 (44%) | |
| Stable disease | 8 (50%) | 9 (56%) | |
| Number of metastatic sites | |||
| One | 6 (38%) | 9 (56%) | |
| Two or more | 10 (63%) | 7 (44%) | |
| Fluoropyrimidine drug used during first-line treatment | |||
| Fluorouracil | 11 (69%) | 10 (63%) | |
| Capecitabine | 5 (33%) | 6 (38%) | |
| Oxaliplatin or irinotecan used during first-line treatment | |||
| Oxaliplatin only | 6 (38%) | 6 (38%) | |
| Irinotecan only | 9 (56%) | 9 (56%) | |
| Neither | 1 (6%) | 1 (6%) | |
| Monoclonal antibody used during first-line treatment | |||
| Cetuximab or panitumumab | 4 (25%) | 3 (19%) | |
| Bevacizumab | 1 (6%) | 1 (6%) | |
| No antibody | 11 (69%) | 12 (75%) | |
Data are number of patients (%) or median (IQR).